Introduction
Isolated growth hormone (GH) deficiency (IGHD) resulting in short stature has an estimated birth incidence of 1 out of 4000-10 000 (Millar et al., 2003) and is usually sporadic, but monogenic forms are known. Involvement of a number of autosomal genes has been demonstrated, including the GH-1 (Wainrajch et al., 1996; Hess et al., 2007) , GH releasing hormone receptor (Wainrajch et al., 1996) , and HESX1 (Thomas et al., 2001) genes. Further molecular heterogeneity is suggested, as the inherited basis of many familial cases remains unclear (Dattani, 2005) . X-linked combined pituitary hormone deficiency has been demonstrated previously to show linkage to two loci. One locus at Xq21.3-q22 is associated with agammaglobulinemia (Conley et al., 1991) , whereas another is associated with the learning disability and spina bifida and results from duplication of Xq26.1-q27.3 (Solomon et al., 2002) . SOX3 lies in this duplicated segment, and is an SRY-related high mobility group box transcription factor expressed in the developing pituitary (Collignon et al., 1996) . In a single large family, Laumonnier et al. (2002) identified an in-frame 33 bp duplication, encoding 11 additional alanines, in the polyalanine tract in SOX3 as the cause for X-linked learning disability associated with GH deficiency. Woods et al. (2005) subsequently demonstrated that a seven alanine repeat duplication in SOX3 could cause congenital hypopituitarism.
Participants and methods

Participants
A large family with several males affected by IGHD was referred to genetics. Their clinical presentation is described below and the pedigree is illustrated in Fig. 1a .
Genetic testing
With informed consent, DNA was prepared from the two probands, indicated with arrows in Fig. 1a , and 10 other family members. The entire open reading frame of SOX3 was sequenced in affected male III:4, with analysis on an ABI 3730 analyser (Applied Biosystems, Foster City, California, USA). A polymerase chain reaction based assay was then designed to allow sizing of the alleles by polyacrylamide gel electrophoresis in this affected male and all other family members. This assay was then used to assess whether the expansion was present in 50 control females of normal stature.
Results
Clinical presentation
Both II:2 and II:6 are sisters whose adult heights are around 155 cm [standard deviation score (SDS) -1.2]. Of their three full brothers, one, II:5, has normal stature, and two short stature, II:3 (152 cm, SDS -3.4) and II:4 (156 cm, SDS -2.8). Their half brother, II:1, also has normal stature (180 cm). All have normal intelligence. The affected brothers II:3 and II:4 had not had imaging investigations and were no longer under follow-up. No distinctive facial characteristics were apparent in either affected males or intervening females.
III:4 presented at 9 years with short stature (height SDS -2.8). Thyroid function was normal and bone age was 7.3 years. Peak GH levels during insulin tolerance and arginine stimulation tests were < 2 and 4.5 mU/l, respectively. Growth velocity over 1.2 years was 3.9 cm/year (< 3rd centile). Human GH treatment was started at 9.2 years, and by 11 years his height SDS had increased to -1.7. He had delayed puberty, and was prescribed Sustanon at 14 years, which continued until 18 years. His final height was 165.2 cm at 18.5 years (height SDS -1.4). Retesting at 18 years confirmed GH deficiency, with no evidence of adrenocorticotropic hormone or thyroid-stimulating hormone deficiency. Testicular volumes were lower than average, but early morning testosterone was at the lower end of the normal range. MRI demonstrated an ectopic posterior pituitary (EPP), (Fig. 1b) . He remains on GH treatment as an adult, is intellectually normal and married. He attended college and runs his own computer company.
III:2, who has normal stature, has a son, IV:1. His birth weight was 4.16 kg (SDS + 1.3) and length 56 cm (SDS + 2.9). His growth was normal until about 5-6 months, but by 12 months, length was 72.5 cm (SDS -1.4). Investigations done because of the family history revealed no bone age delay, but a peak GH level during an arginine stimulation test was 16.2 mU/l. Insulin-like growth factor-I was very low at 29 mg/l (normal 88-474 mg/l). A further GH stimulation test with glucagon showed poor GH reserve (peak 5.1 mU/l), whereas peak GH during sleep was 8.7 mU/l. Computed tomography scanning demonstrated pituitary hypoplasia, whereas MRI showed a small anterior pituitary gland, EPP and absent distal pituitary stalk (Fig. 1b) , classic appearances associated with both IGHD and hypopituitarism. GH replacement therapy was started at 22 months and his growth has normalised. At the age of 4.6 years, his height was 114.5 cm (SDS + 2) and weight 21 kg (SDS + 1.4). His developmental milestones were normal, and at the age of 6 years he was doing well in school.
Genetic testing
A 21 bp in-frame insertion, resulting in the insertion of seven alanine residues within the normal polyalanine tract at amino acids 234-249, was demonstrated in III:4 (Fig. 2a) . By polyacrylamide gel electrophoresis, this expanded allele was also confirmed in two other affected males, II:3 and IV:1 (Fig. 2b) . Intervening females II:6 and III:2 were shown to be heterozygous for the mutation, confirming their obligate carrier status, and it was absent from II:1, II:5, IV:2 (shown), and from III:3, IV:3 and IV:4 (not shown). The mutation therefore cosegregates fully with the GH deficiency phenotype in the family, with a calculated logarithm of the odds ratio score of 2.68. The mutation was not present in 100 normal control females. One further female carrier, III:5, was identified in this family. Her asymptomatic son IV:4 was subsequently able to be discharged from endocrinological follow-up, as he was found to have inherited her normal allele.
Discussion
IGHD can be a difficult diagnosis to confirm on biochemical tests alone. Anterior pituitary hypoplasia, an absent stalk and EPP are useful findings to support the diagnosis of IGHD, and suggesting that the deficiency is likely to be permanent (Tillmann et al., 2000) . The findings in the family described here demonstrate that mutation in SOX3 may be one cause of IGHD in association with such appearances. The larger polyalanine expansion described by Laumonnier et al. (2002) (11 residues) is associated with not only GH deficiency but also learning disability. In contrast, the seven residue expansion described here, and also by Woods et al. (2005) in association with hypopituitarism, is not. This demonstration of a range of phenotypes associated with the different sized expansions mirrors observations of similar mutations in transcription factor genes underlying a number of autosomal Mendelian disorders, including synpolydactyly (HOXD13 -MIM 186000) (Muragaki et al., 1996) , hand-foot genital syndrome (HOXA13 -MIM 140000) (Utsch et al., 2002) and blepharophimosis, ptosis, epicanthus inversus syndrome (FOXL2 -MIM 110100) (Fokstuen et al., 2003) . The growth failure exhibited by affected males in this family was relatively modest compared with the classical GH deficiency. In addition, the contrast between this family's presentation of isolated GH deficiency, and the combined pituitary hormone deficiency described by Woods et al. (2005) demonstrates the interfamilial phenotypic variability that may be seen, even with identically sized expansions. As IGHD is twice as common in males as females, a SOX3 mutation screen in selected affected males may be useful. The presence of pituitary structural abnormality, in particular EPP, may be a useful discriminator, as this was present in both affected individuals scanned in this family. Investigation of further males with IGHD, in particular those with an X-linked family history, could provide additional information regarding mutation prevalence. Early diagnosis of males in families like the one described here allows for optimal management, whereas normal testing results can obviate the need for follow-up of previously at-risk males. Identification of carrier females has genetic counselling implications. 
